<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Yu W</submitter><pubmed_abstract>Inflammatory bowel disease (IBD) is pathologically characterized by an immune response accommodative insufficiency and dysbiosis accompanied by persistent epithelial barrier dysfunction. The Cao-Xiang-Wei-Kang (CW) formula has been utilized to treat gastrointestinal disorders in the clinic. The present study was designed to delineate the pharmacological mechanisms of this formula from different aspects of the etiology of ulcerative colitis (UC), a major subtype of IBD. Dextran sodium sulfate (DSS) was given to mice for a week at a concentration of 2%, and the CW solution was administered for 3 weeks. 16S rRNA gene sequencing and untargeted metabolomics were conducted to examine the changes in the microbiome profile, and biochemical experiments were performed to confirm the therapeutic func</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>946065</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9530714</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation.</pubmed_title><pmcid>PMC9530714</pmcid><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Zheng Y</pubmed_authors><pubmed_authors>Yan J</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Kang C</pubmed_authors><pubmed_authors>Yu W</pubmed_authors><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Shao C</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation.</name><description>Inflammatory bowel disease (IBD) is pathologically characterized by an immune response accommodative insufficiency and dysbiosis accompanied by persistent epithelial barrier dysfunction. The Cao-Xiang-Wei-Kang (CW) formula has been utilized to treat gastrointestinal disorders in the clinic. The present study was designed to delineate the pharmacological mechanisms of this formula from different aspects of the etiology of ulcerative colitis (UC), a major subtype of IBD. Dextran sodium sulfate (DSS) was given to mice for a week at a concentration of 2%, and the CW solution was administered for 3 weeks. 16S rRNA gene sequencing and untargeted metabolomics were conducted to examine the changes in the microbiome profile, and biochemical experiments were performed to confirm the therapeutic func</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-04-08T10:54:41.91Z</modification><creation>2024-12-04T07:48:04.57Z</creation></dates><accession>S-EPMC9530714</accession><cross_references><pubmed>36204231</pubmed><doi>10.3389/fphar.2022.946065</doi></cross_references></HashMap>